---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-389829"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-09-14T11:06:27+00:00"
generated_at: "2026-09-14T11:10:13.006461+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Corbus CANYON-1: CRB-913 hits 5% mean weight loss at 60 mg; all doses p<0.0001

## Summary
- Phase 1b CANYON-1 (NCT07310901): 254 obese adults, 16-week trial; LS mean weight loss vs placebo: 2.8% (20 mg), 3.3% (40 mg), 5.0% (60 mg) at week 12, all p<0.0001.
- Safety: no serious psychiatric AEs, no suicidality; GI AEs milder than oral GLP-1s (vomiting 1.6-8.2% vs 31% for semaglutide 25 mg).
- Discontinuation rate due to AEs 3.1%-13.1%, markedly lower than monlunabant's 13%-42%.
- Data selected for late-breaking presentation at ObesityWeek 2026 (Nov 14-17, 2026).
- Plans FDA engagement and Phase 2 monotherapy start in 1H 2027; evaluating combo with GLP-1 therapy.

## SEC filing metadata
- accession: 0001193125-26-389829
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-09-14T11:06:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/0001193125-26-389829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-389829
- JSON: https://secwatch.observer/filing/0001193125-26-389829.json
- Plain text: https://secwatch.observer/filing/0001193125-26-389829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.